Image source: Getty Images.
Continue Reading Below
Shares ofRetrophin Inc(NASDAQ: RTRX)are off to the races today, up 38% as of 10:30 a.m. ET after the company reported results from an important phase 2 clinical trial.
Retrophin released positive top-line results from its phase 2 DUET study today. This clinical trial was testing the company's compound sparsentan as a potential treatment for focal segmental glomerulosclerosis, or FSGS, a rare kidney disorder can lead to end-stage renal disease.
The results showed that patients who used sparsentan achieved a 45% reduction in proteinuria, or abnormal quantities of protein in the urine. That was more than double the 18.5% reduction observed in the control group who tookirbesartan, which was a statistically significant difference.
Continue Reading Below
The data also showed thatsparsentan was was generally safe and well-tolerated by patients, though anemia was observed in one study participant. However, the patient remained in the study throughout the full eight-week trial period. In addition, every patient who completed the trial entered the ongoing open-label extension study, and the bulk of these patients are still receiving therapy today.
This study looked like a home run all around, so it's no surprise to see Retrophin shares skyrocketing today.
Retrophin isn't the only stock benefiting from today's clinical release. Shares ofLigand Pharmaceuticals (NASDAQ: LGND), a company that acquiresroyalty assets in the biotech space, are also up nearly 6% based on the news. The reason is that Retrophin in-licensed sparsentan from Ligand back in 2012 when Martin Shkreli was still in the top chair. Thus, Ligand has set itself up to profit if sparsentan can find its way to market.
From here Retrophin plans on meeting with the Food and Drug Administration to discuss moving sparsentan to a phase 3 trial.
Since there are currently no approved drugs on the market that treat FSGS, winning regulatory approval could be a huge financial win for Retrophin and Ligand. Some analysts are projecting peak sales of nearly $1 billion, which is a big number for a company that's currently valued at just over $800 million.
The risks here are still quite high, but today'sresults are encouraging. That makes this a must-watch drug for investors in both Retrophin and Ligand.
A secret billion-dollar stock opportunity
The world's biggest tech company forgot to show you something, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here.
Brian Feroldi has no position in any stocks mentioned.Like this article? Follow him onTwitter where he goes by the handle@Longtermmindsetor connect with him on LinkedIn to see more articles like this.
The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.